Low-dose intestinal irradiation enhances the efficacy and prognosis of PD-1 blockade in metastatic non-small cell lung cancer
Key Points
To investigate how low-dose intestinal irradiation affects the efficacy of PD-1 blockade in metastatic non-small cell lung cancer (mNSCLC).
Examined the influence of intestinal irradiation on PD-1 blockade efficacy.
Maintained doses of 1-3 Gy for irradiation.
Assessed changes in gut microbiota and immune responses.
Low-dose intestinal irradiation enhances the response to PD-1 blockade.
Improved patient prognosis observed with intestinal irradiation combined with PD-1 therapy.
Changes in gut microbiota linked to enhanced immune responses.
Abstract
ILDR influences the efficacy of PD-1 blockade in patients with mNSCLC, particularly when SIMRD is maintained within the 1-3 Gy range, likely through modulation of the gut microbiota-metabolite-immune axis.
KI fragen
Like
Bookmark
Share
View Full Paper
KI fragen
Like
Bookmark
Share
View Full Paper
Low-dose intestinal irradiation enhances the efficacy and prognosis of PD-1 blockade in metastatic non-small cell lung cancer | Synapse